Ewing sarcoma

This study tests a new treatment schedule for people with metastatic Ewing sarcoma, a rare and aggressive cancer. The approach uses an intense first attack on cancer cells, followed by targeted strikes and long-term maintenance to wipe out remaining cells. The goal is a cure. The…

This study is testing a personalized peptide vaccine for children and young adults (up to age 30) with metastatic fusion-driven sarcomas (Ewing sarcoma, rhabdomyosarcoma, synovial sarcoma) who have completed standard treatment. The vaccine is custom-made for each patient based on…

This study tests a drug called zilovertamab vedotin in children and young adults whose blood cancers (like certain leukemias and lymphomas) or solid tumors (neuroblastoma, Ewing sarcoma) have come back or not responded to treatment. The goal is to see if the drug is safe and can …

This study tests a combination of two drugs, nilotinib (a pill) and paclitaxel (given by IV), for people with rare advanced cancers that have not responded to standard treatments. The goal is to see if the drugs can shrink or stop tumor growth. About 82 adults with specific rare …

This early-stage trial tests a new drug called INBRX-109 in people with advanced solid tumors, including Ewing sarcoma and colorectal cancer. The drug is designed to attach to a protein on cancer cells and trigger their death. The main goals are to check safety and see if the dru…

This early-phase trial tests the safety and best dose of cabozantinib combined with high-dose ifosfamide in 30 children and adults with sarcomas (like Ewing sarcoma or osteosarcoma) that have returned or not responded to standard chemotherapy. The goal is to find a dose that cont…

This study tests an experimental pill called silmitasertib combined with standard chemotherapy in children and young adults (under 30) whose solid tumors (like neuroblastoma, Ewing sarcoma, or osteosarcoma) have come back or not responded to treatment. The goal is to find a safe …

This study tests two oral drugs, eflornithine (DFMO) and AMXT 1501, in children and young adults up to age 26 with certain cancers that have come back or not responded to treatment. The cancers include neuroblastoma, brain tumors, and sarcomas. The goal is to find a safe dose and…

This study tests a drug called lurbinectedin in people aged 10 and older whose solid tumors (like Ewing sarcoma) have returned after standard treatment. The goal is to see if the drug is safe and can shrink tumors or delay their growth. Participants must have a specific genetic c…

This study tests a drug called tegavivint in children, teens, and young adults whose solid tumors have come back or stopped responding to treatment. The goal is to find the safest dose and see if it can shrink tumors by blocking a key growth signal inside cancer cells. About 147 …

This early-phase study tests the drug TURALIO (pexidartinib) in people aged 3 to 35 whose cancer has not responded to standard treatments. The goal is to find a safe dose and see if it can shrink tumors or control leukemia. Participants take a daily capsule for up to 2 years, wit…

This early-phase trial tests a combination of three drugs—selumetinib, ZEN-3694, and durvalumab—in people with advanced sarcomas, including malignant peripheral nerve sheath tumors (MPNST) linked to NF1. The study first checks safety and dosing, then looks at whether the treatmen…

This phase 2 trial is testing whether adding the antibody drug naxitamab to standard chemotherapy can help children and young adults with Ewing's sarcoma that has not responded to prior treatment. Participants must have a tumor that shows a specific marker called GD2. The study w…

This early-phase trial is testing a drug called xaluritamig (AMG 509) in 50 adults, adolescents, and children with Ewing sarcoma that has relapsed or not responded to prior treatments. The main goals are to find a safe dose and check for side effects. Researchers will also measur…

This early-stage trial tests a new type of cell therapy for children whose embryonal tumors (rhabdomyosarcoma, Ewing sarcoma, neuroblastoma, or Wilms tumor) have returned or not responded to standard treatments. The therapy uses the patient's own immune cells, engineered to bette…

This trial is testing a new type of cell therapy called hBRCA84D CAR T cells in children, teenagers, and young adults with certain sarcomas (rhabdomyosarcoma, Ewing sarcoma, or desmoplastic small round cell tumour) that have come back or not responded to treatment. The therapy in…

This early-stage trial tests a new drug called GAIA-102 in children whose neuroblastoma or other solid tumors have not responded to standard treatments. The study has four groups, testing GAIA-102 alone or combined with other cancer drugs. The main goal is to check safety and fin…

This early-stage trial is testing whether adding disulfiram (a drug used for alcohol dependence) and copper gluconate to a standard chemotherapy (Doxil) is safe for people with sarcomas that have returned or not responded to prior treatments. About 24 participants will take these…

This early-stage study tests whether giving children with high-risk solid tumors a special type of immune cell (called TAA-T) is safe. The cells are designed to recognize and attack proteins found on tumor cells. Up to 36 children whose cancer has not responded to standard treatm…

This study tests whether giving targeted radiation to cancer that has spread (metastasized) can help children, teens, and young adults with sarcoma live longer. About 70 participants with soft tissue or bone sarcoma will receive consolidative radiation therapy to their metastatic…

This phase 1 trial tests a drug called 177Lu-DTPA-omburtamab, which delivers radiation directly to tumor cells in children and teens with recurrent or refractory medulloblastoma or other central nervous system (CNS) tumors that have spread. The drug targets a protein called B7-H3…

This study tests whether adding eflornithine (DFMO) to standard chemotherapy can help teens and young adults with Ewing sarcoma or osteosarcoma live longer without their cancer coming back. About 406 participants will join one of five groups based on their cancer type and stage. …

This early-phase study tests a new drug called DXC008 in people with prostate cancer or other solid tumors (like Ewing sarcoma) who have not responded to standard treatments. The main goals are to check the drug's safety, find the right dose, and see if it can shrink tumors. Abou…

This study tests a special stem cell transplant for children, teens, and young adults (ages 6 months to 25 years) with solid tumors that have come back or not responded to treatment. The transplant uses cells from a donor, with certain immune cells removed to reduce side effects,…

This phase 2 trial tests a daily oral drug called zanzalintinib in 70 adults with advanced or metastatic bone sarcomas that cannot be removed by surgery. The study includes four groups based on sarcoma type. Researchers will check if the drug is safe and helps control the cancer.

This study tests a drug called zanzalintinib (XL092) in 29 people with advanced leiomyosarcoma that has spread or cannot be removed by surgery. The drug works by blocking signals that help cancer cells grow. The goal is to see if it can slow the cancer's progression longer than c…

This study tests a new way of giving radiation therapy for Ewing sarcoma, a rare bone and soft tissue cancer. The radiation dose is tailored to each patient's tumor size and biology, with higher doses given over a shorter time. The goal is to reduce the chance of the cancer retur…

This early-phase trial tests an experimental oral drug called ST-01156 in adults with advanced solid tumors that have spread or cannot be removed by surgery. The drug works by breaking down a protein inside cancer cells. The main goals are to find a safe dose and check for side e…

This study is for children and young adults (ages 1 to 30) whose solid tumors have come back or not gone away with standard treatment. It tests two different drug pairs: one combines Onivyde with talazoparib, the other Onivyde with temozolomide. Both work by damaging cancer cell …

This early-stage trial tests a new immunotherapy for children and young adults up to age 21 with solid tumors that have come back or not responded to standard treatment. The therapy uses the patient's own immune cells, which are modified in a lab to recognize and attack a protein…

This study tests whether DFMO, a drug taken by mouth, can help prevent cancer from coming back in people with relapsed Ewing sarcoma or osteosarcoma who have finished all planned treatment and show no signs of disease. The trial will enroll 15 participants under age 40. The main …

This early-phase trial is testing a new type of immunotherapy called B7-H3 CAR T cells in children and young adults whose solid tumors (such as neuroblastoma, sarcoma, or osteosarcoma) have come back or not responded to standard treatments. The therapy involves taking a patient's…

This early-phase trial tests a four-drug combination—vorinostat plus three chemotherapy drugs—in children, teens, and young adults up to age 30 whose solid tumors or brain cancers have returned or not responded to standard treatment. The main goal is to find the safest dose of vo…

This study is testing a bone marrow transplant from a half-matched family donor for people with high-risk solid tumors that have come back or not responded to treatment. Participants receive mild chemotherapy and radiation before the transplant, along with drugs to prevent reject…

This phase 2 trial tests whether a year-long maintenance regimen of sirolimus (rapamycin) plus low-dose oral chemotherapy and celecoxib can improve 2-year survival without cancer progression in children with high-risk solid tumors. About 55 children and young adults (ages 1–30) w…

This study tests whether the drug regorafenib can help prevent bone sarcomas from coming back after initial treatment. About 168 people aged 12 and older with various bone sarcomas will be randomly assigned to take regorafenib for up to 12 months or to receive standard monitoring…

This phase 2 trial tests whether the drug regorafenib can help keep high-grade bone sarcomas from growing in patients who still have some disease after standard treatment. About 36 people aged 12 and older will take regorafenib daily for up to 12 months. The main goal is to see h…

This study tests a new drug called PEEL-224 combined with two standard chemotherapy drugs (vincristine and temozolomide) in adolescents and young adults whose sarcomas have returned or not responded to treatment. The trial has two phases: first, finding the safest dose, then chec…

This early-stage study tests a new treatment for children and young adults up to age 21 with sarcomas that have come back or not responded to standard therapy. The treatment combines a special type of immune cell (B7-H3-CAR T cells) with targeted radiation and chemotherapy to see…

This study tests a drug called lurbinectedin in children and young adults (ages 2 to 30) with Ewing sarcoma that has returned or not responded to prior treatments. The first part finds the safest dose, and the second part checks if the drug shrinks tumors. About 60 participants w…

This study tests whether adding specially trained donor immune cells (NK cells) to standard chemotherapy can help children and young adults with sarcomas that have returned or not responded to treatment. About 50 participants aged 2 to 40 will receive up to 8 cycles of chemo plus…

This study tests whether a new type of immune cell therapy (HER2-CAR T cells) combined with drugs that boost the immune system (pembrolizumab or nivolumab) is safe for people with advanced sarcoma. About 25 participants will receive chemotherapy before the cell infusion to help t…

This early-phase trial tests a new type of stem cell transplant for children with blood cancers or solid tumors that have relapsed or not responded to standard treatment. Doctors use a half-matched donor's stem cells, specially filtered to remove certain immune cells, and give th…

This study tests two drugs, pembrolizumab and cabozantinib, together in people with advanced sarcomas (cancers of the soft tissue or bone) that have not responded to standard treatments. The goal is to see if the combination can stop or shrink tumors for at least 6 months. About …

This study tests a special dye called Cytalux that makes cancer cells glow under near-infrared light. Surgeons use it during lung surgery to find and remove hard-to-see tumors in teens (ages 6-17) with bone cancer that has spread to the lungs. The goal is to see if the dye helps …

This study looks at two lab tests (RT-qPCR and ddPCR) to find leftover cancer cells in frozen ovarian or testicular tissue from children treated for neuroblastoma or Ewing sarcoma. The goal is to make it safer for these children to later use their stored tissue to have children o…

This early-phase trial tests whether the drug romiplostim can prevent dangerously low platelet levels caused by chemotherapy in children and young adults with newly diagnosed Ewing sarcoma. About 26 participants will receive romiplostim alongside their standard chemotherapy to se…

This study will enroll 100 children with solid tumors or Hodgkin lymphoma who are receiving proton therapy. Researchers will take weekly or bi-weekly CT or MRI scans during treatment to check if the original radiation plan is still accurate. If tumor coverage drops by 5% or radia…

This study investigates whether a blood marker called anti-Müllerian hormone (AMH) can predict future infertility in children and adolescents who have undergone cancer treatment. Many young patients recover normal menstrual cycles or puberty after chemotherapy, but their ovarian …

This early-stage study tests whether people with advanced solid tumors can safely follow a diet low in methionine, an amino acid found in many proteins. Researchers will measure how well participants stick to the diet, check for side effects, and track changes in blood methionine…

This study tests whether changes in a blood protein called ProGRP can signal how well Ewing sarcoma is responding to treatment. Researchers will measure ProGRP levels in 100 newly diagnosed patients before, during, and after chemotherapy, then compare those levels with tumor size…

This study examines blood samples from people with Ewing sarcoma to find circulating biomarkers—substances that might signal the presence or behavior of the cancer. Researchers will compare samples from patients and healthy volunteers to identify markers that could help validate …

This study follows 300 people who had surgery to remove bone tumors (like osteosarcoma or chondrosarcoma). Researchers want to see how well the bone heals and how much function returns over 3 years. Participants fill out questionnaires about their daily activities. No new drug or…

This study looks at whether using 3D printed models of a patient's bones helps surgeons plan and perform tumor removal more effectively. About 150 people with bone tumors will take part, and half will have their surgery planned with both 3D models and regular scans, while the oth…

This study looks at how well bone cancer patients follow a personalized home exercise program in the first six months after lower leg surgery. Researchers will track daily exercise logs from 50 patients and explore what factors help or hinder adherence. The goal is to learn how t…

This study is for people under 50 with a type of bone cancer called Ewing sarcoma. Researchers will collect information about patients' health, treatments, and results over time. The goal is to learn more about the disease and how it is treated, not to test a new drug or therapy.

This study collects tumor and blood samples from 1,000 children with solid cancers like neuroblastoma and sarcoma. Researchers will analyze the genetic makeup and immune response of these tumors to better understand how they grow and resist treatment. The goal is to gather knowle…